Main Article Content
Objective: This study aimed to determine the effects of Liraglutide on glycosylated hemoglobin (HbA1c) and body weight in patients with type 2 diabetes.
Material and Methods: A prospective observational study was conducted in a private tertiary healthcare setting. A total of 58 adult patients with T2DM using oral anti-diabetic agents with or without insulin were enrolled in the study from November 2020 to April 2022. Liraglutide was administered at a dose of 0.6 mg/day which was raised to 1.2 mg/day after 1 week and later to 1.8 mg/day depending upon patient preferences and tolerability. Patients were assessed for changes in their body weight, fasting blood glucose (FBG) level, random blood glucose (RBG) level, and HbA1c at the 1st and 2nd follow-up visits of the 8th and 16th week, respectively.
Results: At the 16th week, the mean weight was 100.78±17.56 vs 102.74±17.26 and 104.11±17.95 at the 8th week and baseline visit, revealing a significant difference across three-time points [F(1.4, 36.45)=8.57, p=0.003]. A post hoc pairwise analysis showed that weight significantly decreased from baseline and 16th-week follow-up visits (p=0.011). Similarly, a significant decrease was observed in mean HbA1c across three-time points [F (2, 39.40) =8.81, p=0.001]. Mean HbA1c at 16th week was 6.61±1.13% vs 8.09±1.43% at baseline (P = 0.001). No significant reduction in FBG, RBG, blood pressure, and serum lipid profile were observed. Moreover, no major side effects occurred in any patient.
Conclusion: Liraglutide is an effective and well-tolerable drug in improving glycemic control, causing significant weight loss in the study population when used as a monotherapy or in combination therapy.
KEYWORDS: Liraglutide, Glucagon-like peptide-1 agonist, Type 2 diabetes mellitus, Glycemic control, Weight loss
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
All articles published in the Journal of Medical Sciences (JMS) are licensed under the Creative Commons Attribution 4.0 International License (CC-BY 4.0). Under the CC BY 4.0 license, author(s) retain the ownership of the copyright publishing rights without restrictions for their content, and allow others to copy, use, print, share, modify, and distribute the content of the article even for commercial purposes as long as the original authors and the journal are properly cited. No permission is required from the author/s or the publishers for this purpose. Appropriate attribution can be provided by simply citing the original article. The corresponding author has the right to grant on behalf of all authors, a worldwide license to JMS and its licensees in all forms, formats, and media (whether known now or created in the future), The corresponding author must certify and warrant the authorship and proprietorship and should declare that he/she has not granted or assigned any of the article’s rights to any other person or body.
The corresponding author must compensate the journal for any costs, expenses, or damages that the JMS may incur as a result of any breach of these warranties including any intentional or unintentional errors, omissions, copyright issues, or plagiarism. The editorial office must be notified upon submission if an article contains materials like text, pictures, tables, or graphs from other copyrighted sources. The JMS reserves the right to remove any images, figures, tables, or other content, from any article, whether before or after publication, if concerns are raised about copyright, license, or permissions and the authors are unable to provide documentation confirming that appropriate permissions were obtained for publication of the content in question.